Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Evoke Pharma (EVOK) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to $105056.0.

  • Evoke Pharma's Share-based Compensation fell 2016.23% to $105056.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $554620.0, marking a year-over-year decrease of 3013.39%. This contributed to the annual value of $773121.0 for FY2024, which is 3146.75% down from last year.
  • Evoke Pharma's Share-based Compensation amounted to $105056.0 in Q3 2025, which was down 2016.23% from $104253.0 recorded in Q2 2025.
  • Evoke Pharma's 5-year Share-based Compensation high stood at $561348.0 for Q1 2021, and its period low was $84384.0 during Q1 2025.
  • For the 5-year period, Evoke Pharma's Share-based Compensation averaged around $291188.7, with its median value being $281758.0 (2023).
  • In the last 5 years, Evoke Pharma's Share-based Compensation skyrocketed by 8098.54% in 2021 and then plummeted by 6678.17% in 2025.
  • Quarter analysis of 5 years shows Evoke Pharma's Share-based Compensation stood at $454200.0 in 2021, then dropped by 21.85% to $354972.0 in 2022, then fell by 20.66% to $281639.0 in 2023, then fell by 7.35% to $260927.0 in 2024, then tumbled by 59.74% to $105056.0 in 2025.
  • Its Share-based Compensation was $105056.0 in Q3 2025, compared to $104253.0 in Q2 2025 and $84384.0 in Q1 2025.